RecruitingPhase 2NCT05661188
Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS)
Studying Carcinoma of the anal canal
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
- Principal Investigator
- Jaume CapdevilaHospital Vall d'Hebron
- Intervention
- Atezolizumab plus Tiraglolumab(drug)
- Enrollment
- 45 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2028
Study locations (15)
- Hospital Universitario Son Espases, Palma de Mallorca, Balearic Islands, Spain
- Institut Català d'Oncologia (ICO) Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain
- Hospital Arnau de Vilanova, Lleida, Barcelona, Spain
- Hospital Sant Joan Despí, Martorell, Barcelona, Spain
- Consorcio Corporación Sanitaria Parc Taulí, Sabadell, Barcelona, Spain
- Hospital General Universitario de Toledo, Toledo, Castille-La Mancha, Spain
- HU Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain
- Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- Hospital Universitari Vall d'Hebron, Barcelona, Spain
- Hospital General de Ciudad Real, Ciudad Real, Spain
- Complejo Asistencial Universitario de León, León, Spain
- Hospital Universitario 12 de Octubre, Madrid, Spain
- Consorcio Hospital General Universitario de Valencia, Valencia, Spain
- Hospital Universitario y Politécnico la Fe de Valencia, Valencia, Spain
- Hospital Universitario Miguel Servet, Zaragoza, Spain
Collaborators
Hoffmann-La Roche
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05661188 on ClinicalTrials.govOther trials for Carcinoma of the anal canal
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07029152Screening for Anal Cancer in Men Who Have Sex With Men Using Pre-Exposure ProphylaxisUniversitair Ziekenhuis Brussel
- ACTIVE NOT RECRUITINGPHASE3NCT06866574A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese MalesXiamen University
- RECRUITINGPHASE2NCT06640283Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical OutcomesInstituto do Cancer do Estado de São Paulo
- RECRUITINGNANCT06792604Host Genome Methylation: a Screening Tool in Anal Cancer DetectionAssistance Publique - Hôpitaux de Paris
- RECRUITINGPHASE3NCT06207981Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCAFederation Francophone de Cancerologie Digestive
- RECRUITINGNCT06327568Anal Cancer and/or Precancer Screening: Performance Analysis of the BD Onclarity™ HPV Assay on Anal SpecimensEuropean Institute of Oncology
- RECRUITINGNCT05438836Re-optimization Based Online Adaptive Radiotherapy of Anal CancerHerlev Hospital
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04432597HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated CancersNational Cancer Institute (NCI)